Please provide your email address to receive an email when new articles are posted on . Mitral annulus calcification may be an independent risk factor for all-cause mortality and was more common among ...

A retrospective review of more than 24,000 patients who underwent an EKG at Mayo Clinic finds that nearly one-quarter of the patients had mitral annulus calcification, a chronic degeneration of tissue ...

Patients with mitral annulus calcification are at more than double the risk for mitral valve dysfunction, a study published June 1 in Mayo Clinic Proceedings found. Researchers retrospectively ...

ROCHESTER, Minn. — A retrospective review of more than 24,000 patients who underwent an EKG at Mayo Clinic finds that nearly one-quarter of the patients had mitral annulus calcification, a chronic ...

Transcatheter implantation of the Tendyne mitral valve replacement device for treatment of mitral regurgitation in patients at prohibitive surgical risk because of severe mitral annular calcification ...

Employing intravascular lithotripsy facilitated transcatheter mitral valve replacement in a patient with severe mitral annular and mitral valve leaflet calcification, according to a report on a ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

The US Food and Drug Administration has approved the Sapien M3 system for transseptal transcatheter mitral valve replacement (TMVR) for use in patients with symptomatic moderate-to-severe mitral ...

SAN FRANCISCO, Oct. 8, 2025 /PRNewswire/ -- Bunkerhill Health today announced that it has received U.S. Food and Drug Administration (FDA) clearance for Bunkerhill MAC, the first artificial ...

Edwards Lifesciences wins FDA approval for SAPIEN M3, the first transseptal TMVR, expanding minimally invasive options for high-risk mitral regurgitation patients.

Edwards Lifesciences announced today that its Sapien M3 mitral valve replacement system received FDA approval for mitral ...

The SAPIEN M3 system received CE Mark in April 2025, making it the world’s first approved transfemoral transcatheter mitral ...